As expected, patients with CLL had significantly decreased levels of CD19+CD27+IgD+ marginal zone B cells (28.92 ± 10.81) when compared to the control group (42.30 ± 9.52), p = 0.0059 (Fig. 2E). Here, CD19 is linked to B-cell chronic lymphocytic leukemia.